# Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

> **NCT01075425** · PHASE1 · COMPLETED · sponsor: **Virginia Commonwealth University** · enrollment: 41 (actual)

## Conditions studied

- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** bortezomib
- **DRUG:** belinostat
- **OTHER:** laboratory biomarker analysis
- **GENETIC:** western blotting
- **OTHER:** pharmacological study
- **OTHER:** flow cytometry

## Key facts

- **NCT ID:** NCT01075425
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2016-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01075425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01075425, "Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01075425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*